ECCO 2017: Pembrolizumab active against mucosal melanoma tumours, prolongs survival for bladder cancer

Clinical trials of a new immunotherapy, pembrolizumab, have shown that it prolongs life significantly for patients with bladder cancer and is active against a rare sub-type of melanoma, called mucosal melanoma. The findings were presented in two...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kf6pK0
via IFTTT